Efficacy, Compliance And Toxicity Factors Are Affecting The Rate Of Normalization Of Body Iron Stores In Thalassemia Patients Using The Deferiprone And Deferoxamine Combination Therapy

REFERENCES

• Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30(2):239–249.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1–2):41–47.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85(5):430–438.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466–475.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Br J Haematol. 2010;150(4):489–490.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008;32(1–2):17–28.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy. Hemoglobin. 2010;34(3):204–209.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, . Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion dependent thalassemia and sickle cell disease. Blood. 2004;103(5):1934–1936.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C . A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects of effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56–252, L1NAll, and their combinations. Curr Med Chem. 2005;12(23):2663–2681.
   PubMed Web of Science ®Google Scholar
• Sheppard L, Kontoghiorghes GJ. Competition between L1, desferrioxamine and other chelators for iron and the effect of other metal ions on iron binding. Arzn Forsch/Drug Res. 1993;43(6): 659–663.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem. 2005;12(23):2695–2709.
   PubMed Web of Science ®Google Scholar
• Boddaert N, Le Quan Sang KH, Rotig A, . Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110(1):401–408.
   PubMed Web of Science ®Google Scholar
• Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. Novel treatment for diabetic nephropathy.J Am Soc Nephrol. 2007;18:329A.
   Google Scholar
• Rajapurkar MM, Beliga R, Shah S. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol. 2007;18:57–58A.
   Google Scholar
• Forni GL, Balocco M, Cremonesi L, . Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 2008;23(6):904–907.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci. (Elite Ed) 2009;1:161–178.
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010;9(2): 20 1–206.
   Web of Science ®Google Scholar
• Aessopos A, Kati M, Farmaki D, . Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Haematol. 2007;86(3):212–215.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Yazman D, Economides Ch, Eracleous E, Kontoghiorghes GJ. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol. Hemoglobin. 2009;33(5):312–322.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Eracleous E, Economides Ch, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting excess cardiac iron loading and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin. 2006;30(2):219–227.
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, . Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27–30.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, . Survival and disease complications in thalassemia major. Ann NY Acad Sci. 1998;850:227–231.
   PubMed Web of Science ®Google Scholar
• Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003;88(12):1423–25.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Introduction of higher doses of deferasirox: Better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opin Drug Saf. 2010;9(4):633–641.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ.A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5):332–338.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin. 2006;30(2):183–200.
   PubMed Web of Science ®Google Scholar
• Wood JC, Kang BP, Thompson A, . The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537–543.
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Capra M, . Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2010;96(1):41–47.
   PubMed Web of Science ®Google Scholar